Anti-infective Agents : Antiretroviral Agents
OCOMP5 “Complera tablet”
Each tablet contains rilpivirine 25 mg, emtricitabine 200 mg, tenofovir disoproxil fumarate 245 mg
適應症：COMPLERA (emtrictabine/rilpivirine/tenofovir disoproxil fumarate)是由兩種核苷類似物反轉錄酶抑制劑(emtrictabine/tenofovir disoproxil fumarate)及一種非核苷反轉錄酶抑制劑(rilpivirine)組成之複方療法，適用於先前未曾使用過抗病毒藥物治療之愛滋病毒(HIV-1)感染之完整治療，且在治療開始時其病毒量HIV-1 RNA≦100,000 copies/mL之成人患者。
Usual dose: 1 tablet (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg) POQD with food.
Dose adjustment:
Renal impairment, moderate, severe, or end-stage (CrCl less than 50 mL/min): not recommended.
Hepatic impairment, mild or moderate: no dosage adjustment required.
Dialysis: not recommended.
Concomitant rifabutin: an additional rilpivirine 25 mg tablet per day is recommended
Adverse effect: Concomitant use with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine, dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, systemic dexamethasone (more than a single dose), or St John’s wort.